1. Home
  2. Syndicated Research

  3. Cancer Diagnostics Market Analysis

Cancer Diagnostics Market

Cancer Diagnostics Market: Biopsy Test Type Segment Expected to Remain Dominant Throughout the Forecast Period: Global Industry Analysis and Opportunity Assessment 2016 - 2026

Ask The Analyst Customization Available Request Methodology

Availability of Advanced Diagnostics at a Reduced Cost to Benefit Cancer Patients Worldwide

After the completion of the human genome project in 2003, the cost of assembling one genome has reduced tremendously and cut down the time of analysis with the development of highly-advanced sequencing equipment. For instance, in January 2014, Illumina Inc. launched the HighSeq X Ten Sequencer, which cut down the cost of genome sequencing to as low as US$ 1,000 including reagents cost, sample preparation equipment depreciation cost, etc. Further advancements may continue to pull down the cost of genome sequencing for cancer diagnosis to less than a cost of an X-ray, which would enhance the accessibility of this technology and thus enhance the adoption of cancer diagnostics. This would also facilitate the use of highly-advanced cancer diagnostic technologies by smaller cancer diagnostics research and clinical laboratories who have less technical expertise and low resources, which is expected to benefit the cancer diagnostics market greatly.

Meeting the Needs of Hospital Laboratories: Huge Opportunity for Players in the Global Cancer Diagnostics Market

Attributing to the healthcare cost containment in a majority of mature markets, hospital-based cancer diagnostic laboratories are facing pressure to supply more services at reduced costs. Healthcare facilities are catering to the increased aging population and witnessing a rise in the prevalence of chronic diseases. By 2018 end, almost 10% of the global population is expected to be aged 65 & above. This imposes cost management pressure on cancer diagnostic laboratories and general diagnostic laboratories. Thus, majority of diagnostic laboratories have started adopting informatics solutions, which help them increase overall productivity within the existing resources. In line with this, manufacturers of diagnostic tests can grab the opportunity to provide complementary services and support to hospital-based cancer diagnostic laboratories. These services would help high-burden cancer diagnostic laboratories to reduce unexpected down time and better manage laboratory workflow. For instance, Abbott Laboratories recently launched AlinIQ support and services to help its laboratory partners manage operations to maximize throughput and capacity. The company is also planning to launch next-generation systems for point-of-care testing, immunoassay, clinical chemistry, molecular diagnostics, etc. BioMérieux’s LEAN lab assessment program is witnessing increased diagnostic laboratory productivity by up to 30%.

Cancer Biomarkers Continue to be the Most Rapidly Advancing Field in Cancer Diagnostics

The number of biomarkers that can be utilized for early cancer detection from blood or plasma samples is continuously expanding, which is expected to bring new cancer biomarker tests in the market in nearest future. These cancer biomarkers can be used as screening tests or cancer diagnostics in the general population or for early diagnosis of specific cancer. Advancements in cancer biomarkers, coupled with the introduction of sophisticated cancer diagnostic technologies such as microarray and automated sequencing would bring about revolutionary changes in the cancer diagnostics market. For instance, researchers at the University of Sheffield have recently identified over 700 new blood biomarkers that can be used for early cancer diagnosis. As per OECD statistics, the global biomarkers market for companion diagnostics was valued at US$ 5.2 Bn in 2012 and raked US$ 8.4 Bn by 2016. The growth in companion diagnostics is indicative of the acceptance of biomarkers in healthcare systems and may offer attractive incentives for biomarkers’ business development in cancer diagnostics.

Despite Advances in Molecular Diagnostics, Imaging Techniques Remain Mainstay in the Cancer Diagnostics Market

Multiple imaging techniques are used in all phases of cancer screening, cancer diagnostic, and treatment management and thus, are an essential part of clinical protocol. Imaging has become an important aspect of cancer screening and cancer diagnosis and recent progress in tumor imaging technologies has improved the diagnosis of five common cancers including breast, lung, prostate and colorectal cancers. For instance, Toshiba Medical Systems Corporation has developed an ultrasound technology MicroPure for the early detection of microcalcification in breast tissue. With the increasing demand for PET cameras, technology has gone evolved to cut down the time for image processing. The introduction of PET/CT has enabled the acquisition of morphological and functional information.

Biopsy Segment Dominates the Global Cancer Diagnostics Market in Terms of Revenue

For a majority of cancers, biopsy is the primary test a physician would prescribe and thus, it holds the largest share in the global cancer diagnostics market. Even though liquid biopsy is becoming more popular due to its non-invasive nature, to obtain an accurate diagnosis, solid tumour biopsies or tissue biopsies are still preferred. New developments in fine needle aspiration tools for cancer diagnosis for different indications including lung cancers, head and neck cancers, advanced breast cancer among others have led to the increased demand for tissue biopsy. Majority of lung cancers are diagnosed in the late stage of where fine needle aspiration biopsy is the only possible test done to confirm the cancer presence.

Lung Cancer Indication Segment is the Most Lucrative for Manufacturers of Cancer Diagnostics

Lung cancer is one of the most common cancers across the globe and is the cause for thousands of deaths each year. However, the incidence and pattern of lung cancer show huge variations among geographic regions, ethnicity, etc. The screening of lung cancer patients, thus, presents difficulties to healthcare systems across the globe. In one recent study by All India Institute of Medical Sciences India, screening of lung cancer patients with low dose computed tomography (CT) showed ~20% reduction in lung cancer deaths, but with 95% false positive rate. New techniques of lung cancer diagnostic and screening are thus immediately needed. The development of specialized biomarker tests for non-small cell lung cancer by key players in the cancer diagnostic industry is expected to benefit patients. In 2014, Medicare spent US$ 38.3 Mn on lung cancer diagnosis in the U.S. and biopsy held a significant proportion of the lung cancer diagnostic tests conducted in 2014.

Competitive Landscape

The FMI report provides detailed information about growth parameters in the cancer diagnostics market with the help of a detailed assessment of the competitive environment in the global cancer diagnostics market. The global cancer diagnostics market study provides comprehensive data on important stakeholders in the cancer diagnostics market including Abbott Laboratories, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Siemens Healthineers, Bio Rad Laboratories Inc., GE Healthcare, Illumina, Inc., Koninklijke Philips N.V., Toshiba Medical Systems Corporation, Agilent Technologies, Inc. etc. among others.

Major players in the cancer diagnostics market are focusing on maximizing their market penetration in the install base. The development of molecular diagnostic tests run on specialized instruments and development of these instruments require huge investment of money and time. Thus, addressing the huge needs in cancer diagnostics requires the participation of established diagnostics industry players. Majority of the cancer diagnostic companies place these instruments into diagnostic and research laboratories through reagent rental contracts, in exchange for long-term contracts to purchase test reagents, as these cancer diagnostic tests can only be run in laboratories possessing instruments for which the test is developed and approved. Moreover, newly developed cancer diagnostic tests for particular instruments need to be mass marketed to diagnostic laboratories, general practitioners, and health insurers. For instance, Epigenomics AG, a U.S.-based molecular diagnostics lab and one of the major players in the cancer diagnostic market, employs a unique strategy of non-exclusive licensing for its newly launched cancer diagnostic tests to increase the penetration of its new products in the global cancer diagnostics market. Big players such as Roche Diagnostics and Abbott license their cancer diagnostic test products to regional geographical partners who either distribute these products in the region or develop reagent kits for their instruments. 

Definition

Cancer diagnostics include cancer screening tests performed among the general population or high-risk population, specific cancer diagnostic tests or confirmatory tests and tests to track the prognosis of disease and treatment. The global report cancer diagnostics market report includes market size for all the above mentioned tests for cancer diagnosis.

About the Report

The study on the cancer diagnostics market, recently published by FMI, provides comprehensive information about the most important market dynamics that will prove instrumental in the growth of cancer diagnostics market during 2016-2026. Market players can find the most accurate quantitative and qualitative information about growth parameters in the cancer diagnostics market in the report, which will help them to develop data-driven business strategies in the coming future.

Segmentation

For the better understanding of readers, the FMI cancer diagnostics market report provides salient information about the cancer diagnostics market in the most comprehensive manner. The cancer diagnostics market has been segmented according to geographical regions, test types, applications/indications and end users to analyze the segment-wise growth of the cancer diagnostics market. Based on geographical regions, the cancer diagnostics market has been segmented into North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific Excluding Japan (APEJ), Japan and the Middle East & Africa (MEA). On the basis of test type, the cancer diagnostics market has been segmented into tumour biomarker tests, imaging tests, biopsy, liquid biopsy, immunohistochemistry, in-situ hybridization. Furthermore, based on application/indication, the global cancer diagnostic market has been segmented into breast cancer, lung cancer, colorectal cancer, melanoma, blood cancer, prostate cancer, ovarian cancer, stomach cancer and liver cancer. Based on end users, the global cancer diagnostics market has been divided into hospital associated diagnostic laboratories, independent diagnostic laboratories, diagnostic imaging centers, cancer research institutes and others.

Additional Questions Answered

Readers can find detailed information about the important factors that are supporting and hampering the growth of the cancer diagnostics market during the forecast period in this report. Additionally, the report also contains valuable information about cancer diagnostics market players with answers to critical questions, such as:

  • Which test types are commonly prescribed for each cancer diagnosis?

  • How has the global cancer diagnostics market evolved over time?

  • Which regulations in various regional segments are influencing the strategies of players in the cancer diagnostics market?

  • What is the potential population/volume of the cancer diagnostics market?

Research Methodology

The process of market research followed at FMI commences with an extensive secondary research of the cancer diagnostics market. Analysts obtain industry-validated, historic and current data about the demand and sales of all approved cancer diagnostics across the globe. Crude incidence rates for each of the cancers mentioned above in the report scope are obtained on a country level. Diagnostic rates for each cancer, patient journey from cancer screening to diagnosis, percentage prescriptions for various diagnostic tests performed for each cancer type, number of tests per person, etc. are some other factors obtained through in depth primary interviews for each country within the scope. These factors and costs of tests are then utilized to arrive at the final market value for the cancer diagnostics market. The comprehensive secondary research is then followed by primary research, where detailed information about the cancer diagnostics market is obtained in terms of value (US$ million). Based on thorough secondary and primary research of growth parameters in the cancer diagnostics market, analysts come up with the most precise forecast on how cancer diagnostics market will grow over the forecast period.

Cancer Diagnostics Market: Detailed Competitive Analysis Helps Market Players Identify Competitive Positions in the Global Market

A recent market study published by Future Market Insights titled “Cancer Diagnostics Market: Global Industry Analysis and Opportunity Assessment 2016–2026” consists of a comprehensive assessment of the most important market dynamics. The report provides a historical analysis of the cancer diagnostic market during the period of 2014-2016 and a forecast for 2016–2026. The report provides emerging trends and opportunities in the global market, which can help market players design their manufacturing, product or business strategies and exploit the maximum growth potential in the global cancer diagnostics market. It also provides an analysis of the market dynamics in the most comprehensive way for the better understanding of readers.

Section 1 – Executive Summary

The report begins with an executive summary of the cancer diagnostics market, which includes the global market overview and key findings. The section also includes market value (US$ Mn) estimates for the key segments of the global cancer diagnostics s market.

Section 2 – Market Introduction

This section provides a detailed taxonomy and definition of each segment in the global cancer diagnostics market. The section helps readers understand the scope of the report, inclusion and exclusion criteria for different test types within the scope, etc. This section also provides the evolution of the market.

Section 3 –Market Scenario

This section provides current market value and forecast for global cancer diagnostics market over the period of 2015–2026. The section highlights the major forces acting on the market.

Section 4 – Market Dynamics

This chapter provides readers with information regarding the most important macroeconomic and microeconomic factors that are responsible for changes in the cancer diagnostics market. It helps readers understand the critical market dynamics such as drivers, restraints, market trends, and opportunities for market players in the cancer diagnostics market. The section explains a regulatory landscape for cancer diagnostics in matured markets of the U.S., Europe and Japan. A comparative analysis of regulatory pathways provides reader knowledge on difference in technical regulatory requirements in in all three matured markets. The section also provides an overview on the epidemiology of various cancers by region, which helps market players identify the potential population in each region.

Section 5 – Global Cancer Diagnostics Market Analysis & Forecast by Test Type, 2016 – 2026

Based on the test types for cancer diagnosis, this section elaborates the market size for individual test types including tumour biomarker tests, imaging tests, biopsy, liquid biopsy, immunohistochemistry, in-situ hybridization, etc. The section explains a comparative trend analysis and market attractiveness analysis for each segment.

Section 6 – Global Cancer Diagnostics Market Analysis & Forecast by Indication, 2016 – 2026

This section provides market analysis on various cancer indications including breast cancer, lung cancer, colorectal cancer, melanoma, blood cancer, prostate cancer, ovarian cancer, stomach cancer, liver cancer and others. The absolute $ opportunity analysis helps to gain an idea of year over year growth opportunity for different cancer indications.

Section 7 – Global Cancer Diagnostics Market Analysis & Forecast by End User, 2016 – 2026

End-user analysis provides an analysis of the usage pattern of cancer diagnostics across various end users on a global level. Market attractive analysis by end users is also discussed to fathom relative lucrativeness of different end users of cancer diagnostic products.

Section 8 – Global Cancer Diagnostics Market Analysis & Forecast by Region, 2016 – 2026

From a geographical perspective, the global cancer diagnostics market has been analyzed on a total of seven regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding Japan (APEJ), Japan and the Middle East and Africa (MEA). Historical trends in the cancer diagnostics market and their effects on the global market performance is discussed in this section.

Section 9 – North America Cancer Diagnostics Market Analysis and Forecast 2016 – 2026

Readers can find detailed information about factors such as key regulations, pricing analysis, and regional trends that are impacting the growth of the North America cancer diagnostics market. This section also includes the growth prospects of the cancer diagnostics market in countries such as the U.S. and Canada.

Section 10 – Latin America Cancer Diagnostics Market Analysis and Forecast 2016 – 2026

The market performance of cancer diagnostics in North America is discussed on a country level (Brazil, Mexico & rest of Latin America) in this section. The section also provides insights on regional market trends in the Latin America cancer diagnostics market.

Section 11 – Western Europe Cancer Diagnostics Market Analysis and Forecast 2016 – 2026

This section provides a country-wise analysis of the cancer diagnostics market in Western Europe. Countries covered in this section are Germany, Italy, France, the U.K., Spain, Nordic countries, BENELUX and the rest of Western Europe. Market attractiveness analysis by country is provided to identify the growth potential in individual markets. The section highlights regional market trends and key regulations for the cancer diagnostics market.

Section 12 – Eastern Europe Cancer Diagnostics Market Analysis and Forecast 2016 – 2026

This section of the report introduces cancer diagnostics market in Russia, Poland and rest of Eastern Europe by providing detailed information about the growth avenues for market players in the region and growth prospects of the market based on its leading segments.

Section 13 – APEJ Cancer Diagnostics Market Analysis and Forecast 2016 – 2026

China, India, ASEAN, and Australia & New Zealand are the leading countries in the APEJ region that are the prime subject of assessment to obtain growth prospects of the APEJ cancer diagnostics market in this chapter. Readers can find thorough information about the growth parameters of the APEJ cancer diagnostics market during the period 2016 – 2026.

Section 14 – Japan Cancer Diagnostics Market Analysis and Forecast 2016 – 2026

Readers can find important factors that can make a huge impact on the growth of the cancer diagnostics market in Japan This chapter provides the overview of regulations, drivers, restraints, and trends in the Japan cancer diagnostics market.

Section 15 – MEA Cancer Diagnostics Market Analysis and Forecast 2016 – 2026

This chapter provides information on how cancer diagnostics market will grow in the major countries in MEA region, such as GCC Countries, South Africa, and rest of MEA during the period 2013 – 2028.

Section 16 – Competition Landscape, Company Share and Company Profiles

This section provides a dashboard review of the competition in the global cancer diagnostics market. It details the comparative assessment of the key products specific to market segments and competitive position of the key players in the global market.

Readers can find a comprehensive profiles of key players in the cancer diagnostics market, including company overview, revenue shares, strategic overview, and recent company developments, SWOT analysis etc. Company share analysis is provided to understand the degree of competition in the global cancer diagnostics market. Market players featured in the report include Abbott Laboratories, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Siemens Healthineers, Bio Rad Laboratories Inc., GE Healthcare, Illumina, Inc., Koninklijke Philips N.V., Toshiba Medical Systems Corporation and Agilent Technologies, Inc., among others.

Section 17 – Assumptions and Acronyms

This section includes a list of acronyms and assumptions that provide a base to the information and statistics included in the report. The section also enlists forecast assumptions and forecast factors considered while estimating the market size.

Section 18 – Research Methodology

This section helps readers to understand the research methodology followed to obtain various conclusions, important qualitative information, and quantitative information about the cancer diagnostics market.

Cancer Diagnostics Market Reports - Table of Contents

1. Executive Summary

2. Market Introduction

    2.1. Market Definition

    2.2. Market Taxonomy

3. Global Cancer Diagnostics Market Analysis Scenario

    3.1. Market Size (US$ Mn) and Forecast

        3.1.1. Market Size and Y-o-Y Growth

        3.1.2. Absolute $ Opportunity

4. Market Dynamics

    4.1. Macro-economic Factors

    4.2. Drivers

        4.2.1. Supply Side

        4.2.2. Demand Side

    4.3. Restraints

    4.4. Opportunity

    4.5. Forecast Factors – Relevance and Impact

    4.6. Key Industry Developments

    4.7. Cancer Epidemiology, By Region

    4.8. Cancer Diagnostics Regulatory and Reimbursement Scenario

    4.9. Porter’s Analysis 

    4.10. Next-generation Sequencing: A Breakthrough in Cancer Diagnostics

5. Global Cancer Diagnostics Market Analysis and Forecasts, By Test Type 

    5.1. Introduction

    5.2. Basis Point Share (BPS) Analysis By Test Type

    5.3. Y-o-Y Growth Projections By Test Type

    5.4. Market Value Forecast By Test, 2016–2026

        5.4.1. Tumor Biomarkers Tests

            5.4.1.1. PSA Tests

            5.4.1.2. CTC Tests

            5.4.1.3. AFP Tests

            5.4.1.4. CA-19 Tests

            5.4.1.5. HER2 Tests

            5.4.1.6. BRCA Tests

            5.4.1.7. ALK Tests

            5.4.1.8. CEA Tests

            5.4.1.9. EGFR Mutation Tests

            5.4.1.10. KRAS Mutation Tests

            5.4.1.11. Others

        5.4.2. Imaging

            5.4.2.1. Ultrasound

            5.4.2.2. Mammography

            5.4.2.3. MRI Scan

            5.4.2.4. PET Scan

            5.4.2.5. CT Scan

            5.4.2.6. SPECT & Others

        5.4.3. Biopsy

            5.4.3.1. Needle Biopsy

            5.4.3.2. Endoscopic Biopsy

            5.4.3.3. Bone Marrow Biopsy

            5.4.3.4. Others

        5.4.4. Liquid Biopsy

        5.4.5. Immunohistochemistry

        5.4.6. In Situ Hybridization

    5.5. Market Attractiveness Analysis By Test Type

6. Global Cancer Diagnostics Market Analysis and Forecasts, By End User 

    6.1. Introduction

    6.2. Basis Point Share (BPS) Analysis By End User 

    6.3. Y-o-Y Growth Projections By End User 

    6.4. Market Value Forecast By End User, 2016–2026

        6.4.1. Hospital Associated Labs

        6.4.2. Independent Diagnostic Laboratories

        6.4.3. Diagnostic Imaging Centers

        6.4.4. Cancer Research Institutes

        6.4.5. Others

    6.5. Market Attractiveness Analysis By End User 

7. Global Cancer Diagnostics Market Analysis and Forecasts, By Indication 

    7.1. Introduction

    7.2. Basis Point Share (BPS) Analysis By Indication 

    7.3. Y-o-Y Growth Projections By Indication 

    7.4. Market Value Forecast By Indication, 2016–2026

        7.4.1. Breast Cancer

        7.4.2. Lung Cancer

        7.4.3. Colorectal Cancer

        7.4.4. Melanoma

        7.4.5. Blood Cancers

        7.4.6. Prostate Cancer

        7.4.7. Ovarian Cancer

        7.4.8. Stomach Cancer

        7.4.9. Liver Cancer

        7.4.10. 4.10 .Others

    7.5. Market Attractiveness Analysis By Indication 

8. Global Cancer Diagnostics Market Analysis and Forecasts, By Region

    8.1. Basis Point Share (BPS) Analysis By Region

    8.2. Y-o-Y Growth Projections By Region

    8.3. Market Value Forecast By Region

        8.3.1. North America 

        8.3.2. Latin America 

        8.3.3. Western Europe 

        8.3.4. Eastern Europe 

        8.3.5. APEJ 

        8.3.6. Japan 

        8.3.7. MEA 

    8.4. Market Attractiveness Analysis By Region

9. North America Cancer Diagnostics Market Analysis and Forecast

    9.1. Introduction

        9.1.1. Basis Point Share (BPS) Analysis By Country

        9.1.2. Y-o-Y Growth Projections By Country

    9.2. Market Value Forecast By Test, 2016–2026

        9.2.1. Tumor Biomarkers Tests

            9.2.1.1. PSA Tests

            9.2.1.2. CTC Tests

            9.2.1.3. AFP Tests

            9.2.1.4. CA-19 Tests

            9.2.1.5. HER2 Tests

            9.2.1.6. BRCA Tests

            9.2.1.7. ALK Tests

            9.2.1.8. CEA Tests

            9.2.1.9. EGFR Mutation Tests

            9.2.1.10. KRAS Mutation Tests

            9.2.1.11. Others

        9.2.2. Imaging

            9.2.2.1. Ultrasound

            9.2.2.2. Mammography

            9.2.2.3. MRI Scan

            9.2.2.4. PET Scan

            9.2.2.5. CT Scan

            9.2.2.6. SPECT & Others

        9.2.3. Biopsy

            9.2.3.1. Needle Biopsy

            9.2.3.2. Endoscopic Biopsy

            9.2.3.3. Bone Marrow Biopsy

            9.2.3.4. Others

        9.2.4. Liquid Biopsy

        9.2.5. Immunohistochemistry

        9.2.6. In Situ Hybridization

    9.3. Market Value Forecast By End User, 2016–2026

        9.3.1. Hospital Associated Labs

        9.3.2. Independent Diagnostic Laboratories

        9.3.3. Diagnostic Imaging Centers

        9.3.4. Cancer Research Institutes

        9.3.5. Others

    9.4. Market Value Forecast By Indication, 2016–2026

        9.4.1. Breast Cancer

        9.4.2. Lung Cancer

        9.4.3. Colorectal Cancer

        9.4.4. Melanoma

        9.4.5. Blood Cancers

        9.4.6. Prostate Cancer

        9.4.7. Ovarian Cancer

        9.4.8. Stomach Cancer

        9.4.9. Liver Cancer

        9.4.10. Others

    9.5. Market Value Forecast By Country, 2016–2026

        9.5.1. U.S.

        9.5.2. Canada

    9.6. Market Attractiveness Analysis

        9.6.1. By Test 

        9.6.2. By End User 

        9.6.3. By Indication 

        9.6.4. By Country

    9.7. Drivers and Restraints: Impact Analysis 

10. Latin America Cancer Diagnostics Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Basis Point Share (BPS) Analysis By Country

        10.1.2. Y-o-Y Growth Projections By Country

    10.2. Market Value Forecast By Test, 2016–2026

        10.2.1. Tumor Biomarkers Tests

            10.2.1.1. PSA Tests

            10.2.1.2. CTC Tests

            10.2.1.3. AFP Tests

            10.2.1.4. CA-19 Tests

            10.2.1.5. HER2 Tests

            10.2.1.6. BRCA Tests

            10.2.1.7. ALK Tests

            10.2.1.8. CEA Tests

            10.2.1.9. EGFR Mutation Tests

            10.2.1.10. KRAS Mutation Tests

            10.2.1.11. Others

        10.2.2. Imaging

            10.2.2.1. Ultrasound

            10.2.2.2. Mammography

            10.2.2.3. MRI Scan

            10.2.2.4. PET Scan

            10.2.2.5. CT Scan

            10.2.2.6. SPECT & Others

        10.2.3. Biopsy

            10.2.3.1. Needle Biopsy

            10.2.3.2. Endoscopic Biopsy

            10.2.3.3. Bone Marrow Biopsy

            10.2.3.4. Others

        10.2.4. Liquid Biopsy

        10.2.5. Immunohistochemistry

        10.2.6. In Situ Hybridization

    10.3. Market Value Forecast By End User, 2016–2026

        10.3.1. Hospital Associated Labs

        10.3.2. Independent Diagnostic Laboratories

        10.3.3. Diagnostic Imaging Centers

        10.3.4. Cancer Research Institutes

        10.3.5. Others

    10.4. Market Value Forecast By Indication, 2016–2026

        10.4.1. Breast Cancer

        10.4.2. Lung Cancer

        10.4.3. Colorectal Cancer

        10.4.4. Melanoma

        10.4.5. Blood Cancers

        10.4.6. Prostate Cancer

        10.4.7. Ovarian Cancer

        10.4.8. Stomach Cancer

        10.4.9. Liver Cancer

        10.4.10. 4.10 .Others

    10.5. Market Value Forecast By Country, 2016–2026

        10.5.1. Brazil

        10.5.2. Mexico

        10.5.3. Rest of Latin America

    10.6. Market Attractiveness Analysis

        10.6.1. By Test 

        10.6.2. By End User 

        10.6.3. By Indication 

        10.6.4. By Country

    10.7. Drivers and Restraints: Impact Analysis 

11. Western Europe Cancer Diagnostics Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Basis Point Share (BPS) Analysis By Country

        11.1.2. Y-o-Y Growth Projections By Country

    11.2. Market Value Forecast By Test, 2016–2026

        11.2.1. Tumor Biomarkers Tests

            11.2.1.1. PSA Tests

            11.2.1.2. CTC Tests

            11.2.1.3. AFP Tests

            11.2.1.4. CA-19 Tests

            11.2.1.5. HER2 Tests

            11.2.1.6. BRCA Tests

            11.2.1.7. ALK Tests

            11.2.1.8. CEA Tests

            11.2.1.9. EGFR Mutation Tests

            11.2.1.10. KRAS Mutation Tests

            11.2.1.11. Others

        11.2.2. Imaging

            11.2.2.1. Ultrasound

            11.2.2.2. Mammography

            11.2.2.3. MRI Scan

            11.2.2.4. PET Scan

            11.2.2.5. CT Scan

            11.2.2.6. SPECT & Others

        11.2.3. Biopsy

            11.2.3.1. Needle Biopsy

            11.2.3.2. Endoscopic Biopsy

            11.2.3.3. Bone Marrow Biopsy

            11.2.3.4. Others

        11.2.4. Liquid Biopsy

        11.2.5. Immunohistochemistry

        11.2.6. In Situ Hybridization

    11.3. Market Value Forecast By End User, 2016–2026

        11.3.1. Hospital Associated Labs

        11.3.2. Independent Diagnostic Laboratories

        11.3.3. Diagnostic Imaging Centers

        11.3.4. Cancer Research Institutes

        11.3.5. Others

    11.4. Market Value Forecast By Indication, 2016–2026

        11.4.1. Breast Cancer

        11.4.2. Lung Cancer

        11.4.3. Colorectal Cancer

        11.4.4. Melanoma

        11.4.5. Blood Cancers

        11.4.6. Prostate Cancer

        11.4.7. Ovarian Cancer

        11.4.8. Stomach Cancer

        11.4.9. Liver Cancer

        11.4.10. Others

    11.5. Market Value Forecast By Country, 2016–2026

        11.5.1. Germany

        11.5.2. Italy

        11.5.3. France

        11.5.4. K.

        11.5.5. Spain

        11.5.6. Rest of Western Europe

    11.6. Market Attractiveness Analysis

        11.6.1. By Test 

        11.6.2. By End User 

        11.6.3. By Indication 

        11.6.4. By Country

    11.7. Drivers and Restraints: Impact Analysis 

12. Eastern Europe Cancer Diagnostics Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Basis Point Share (BPS) Analysis By Country

        12.1.2. Y-o-Y Growth Projections By Country

    12.2. Market Value Forecast By Test, 2016–2026

        12.2.1. Tumor Biomarkers Tests

            12.2.1.1. PSA Tests

            12.2.1.2. CTC Tests

            12.2.1.3. AFP Tests

            12.2.1.4. CA-19 Tests

            12.2.1.5. HER2 Tests

            12.2.1.6. BRCA Tests

            12.2.1.7. ALK Tests

            12.2.1.8. CEA Tests

            12.2.1.9. EGFR Mutation Tests

            12.2.1.10. KRAS Mutation Tests

            12.2.1.11. Others

        12.2.2. Imaging

            12.2.2.1. Ultrasound

            12.2.2.2. Mammography

            12.2.2.3. MRI Scan

            12.2.2.4. PET Scan

            12.2.2.5. CT Scan

            12.2.2.6. SPECT & Others

        12.2.3. Biopsy

            12.2.3.1. Needle Biopsy

            12.2.3.2. Endoscopic Biopsy

            12.2.3.3. Bone Marrow Biopsy

            12.2.3.4. Others

        12.2.4. Liquid Biopsy

        12.2.5. Immunohistochemistry

        12.2.6. In Situ Hybridization

    12.3. Market Value Forecast By End User, 2016–2026

        12.3.1. Hospital Associated Labs

        12.3.2. Independent Diagnostic Laboratories

        12.3.3. Diagnostic Imaging Centers

        12.3.4. Cancer Research Institutes

        12.3.5. Others

    12.4. Market Value Forecast By Indication, 2016–2026

        12.4.1. Breast Cancer

        12.4.2. Lung Cancer

        12.4.3. Colorectal Cancer

        12.4.4. Melanoma

        12.4.5. Blood Cancers

        12.4.6. Prostate Cancer

        12.4.7. Ovarian Cancer

        12.4.8. Stomach Cancer

        12.4.9. Liver Cancer

        12.4.10. Others

    12.5. Market Value Forecast By Country, 2016–2026

        12.5.1. Russia

        12.5.2. Poland

        12.5.3. Rest of Eastern Europe

    12.6. Market Attractiveness Analysis

        12.6.1. By Test 

        12.6.2. By End User 

        12.6.3. By Indication 

        12.6.4. By Country

    12.7. Drivers and Restraints: Impact Analysis 

13. APEJ Cancer Diagnostics Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Basis Point Share (BPS) Analysis By Country

        13.1.2. Y-o-Y Growth Projections By Country

    13.2. Market Value Forecast By Test, 2016–2026

        13.2.1. Tumor Biomarkers Tests

            13.2.1.1. PSA Tests

            13.2.1.2. CTC Tests

            13.2.1.3. AFP Tests

            13.2.1.4. CA-19 Tests

            13.2.1.5. HER2 Tests

            13.2.1.6. BRCA Tests

            13.2.1.7. ALK Tests

            13.2.1.8. CEA Tests

            13.2.1.9. EGFR Mutation Tests

            13.2.1.10. KRAS Mutation Tests

            13.2.1.11. Others

        13.2.2. Imaging

            13.2.2.1. Ultrasound

            13.2.2.2. Mammography

            13.2.2.3. MRI Scan

            13.2.2.4. PET Scan

            13.2.2.5. CT Scan

            13.2.2.6. SPECT & Others

        13.2.3. Biopsy

            13.2.3.1. Needle Biopsy

            13.2.3.2. Endoscopic Biopsy

            13.2.3.3. Bone Marrow Biopsy

            13.2.3.4. Others

        13.2.4. Liquid Biopsy

        13.2.5. Immunohistochemistry

        13.2.6. In Situ Hybridization

    13.3. Market Value Forecast By End User, 2016–2026

        13.3.1. Hospital Associated Labs

        13.3.2. Independent Diagnostic Laboratories

        13.3.3. Diagnostic Imaging Centers

        13.3.4. Cancer Research Institutes

        13.3.5. Others

    13.4. Market Value Forecast By Indication, 2016–2026

        13.4.1. Breast Cancer

        13.4.2. Lung Cancer

        13.4.3. Colorectal Cancer

        13.4.4. Melanoma

        13.4.5. Blood Cancers

        13.4.6. Prostate Cancer

        13.4.7. Ovarian Cancer

        13.4.8. Stomach Cancer

        13.4.9. Liver Cancer

        13.4.10. 4.10 .Others

    13.5. Market Value Forecast By Country, 2016–2026

        13.5.1. China

        13.5.2. India

        13.5.3. Australia and New Zealand

        13.5.4. ASEAN

        13.5.5. Rest of APEJ

    13.6. Market Attractiveness Analysis

        13.6.1. By Test 

        13.6.2. By End User 

        13.6.3. By Indication 

        13.6.4. By Country

    13.7. Drivers and Restraints: Impact Analysis 

14. Japan Cancer Diagnostics Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Basis Point Share (BPS) Analysis By Country

        14.1.2. Y-o-Y Growth Projections By Country

    14.2. Market Value Forecast By Test, 2016–2026

        14.2.1. Tumor Biomarkers Tests

            14.2.1.1. PSA Tests

            14.2.1.2. CTC Tests

            14.2.1.3. AFP Tests

            14.2.1.4. CA-19 Tests

            14.2.1.5. HER2 Tests

            14.2.1.6. BRCA Tests

            14.2.1.7. ALK Tests

            14.2.1.8. CEA Tests

            14.2.1.9. EGFR Mutation Tests

            14.2.1.10. KRAS Mutation Tests

            14.2.1.11. Others

        14.2.2. Imaging

            14.2.2.1. Ultrasound

            14.2.2.2. Mammography

            14.2.2.3. MRI Scan

            14.2.2.4. PET Scan

            14.2.2.5. CT Scan

            14.2.2.6. SPECT & Others

        14.2.3. Biopsy

            14.2.3.1. Needle Biopsy

            14.2.3.2. Endoscopic Biopsy

            14.2.3.3. Bone Marrow Biopsy

            14.2.3.4. Others

        14.2.4. Liquid Biopsy

        14.2.5. Immunohistochemistry

        14.2.6. In Situ Hybridization

    14.3. Market Value Forecast By End User, 2016–2026

        14.3.1. Hospital Associated Labs

        14.3.2. Independent Diagnostic Laboratories

        14.3.3. Diagnostic Imaging Centers

        14.3.4. Cancer Research Institutes

        14.3.5. Others

    14.4. Market Value Forecast By Indication, 2016–2026

        14.4.1. Breast Cancer

        14.4.2. Lung Cancer

        14.4.3. Colorectal Cancer

        14.4.4. Melanoma

        14.4.5. Blood Cancers

        14.4.6. Prostate Cancer

        14.4.7. Ovarian Cancer

        14.4.8. Stomach Cancer

        14.4.9. Liver Cancer

        14.4.10. Others

    14.5. Market Attractiveness Analysis

        14.5.1. By Test 

        14.5.2. By End User 

        14.5.3. By Indication 

    14.6. Drivers and Restraints: Impact Analysis 

15. MEA Cancer Diagnostics Market Analysis and Forecast

    15.1. Introduction

        15.1.1. Basis Point Share (BPS) Analysis By Country

        15.1.2. Y-o-Y Growth Projections By Country

    15.2. Market Value Forecast By Test, 2016–2026

        15.2.1. Tumor Biomarkers Tests

            15.2.1.1. PSA Tests

            15.2.1.2. CTC Tests

            15.2.1.3. AFP Tests

            15.2.1.4. CA-19 Tests

            15.2.1.5. HER2 Tests

            15.2.1.6. BRCA Tests

            15.2.1.7. ALK Tests

            15.2.1.8. CEA Tests

            15.2.1.9. EGFR Mutation Tests

            15.2.1.10. KRAS Mutation Tests

            15.2.1.11. Others

        15.2.2. Imaging

            15.2.2.1. Ultrasound

            15.2.2.2. Mammography

            15.2.2.3. MRI Scan

            15.2.2.4. PET Scan

            15.2.2.5. CT Scan

            15.2.2.6. SPECT & Others

        15.2.3. Biopsy

            15.2.3.1. Needle Biopsy

            15.2.3.2. Endoscopic Biopsy

            15.2.3.3. Bone Marrow Biopsy

            15.2.3.4. Others

        15.2.4. Liquid Biopsy

        15.2.5. Immunohistochemistry

        15.2.6. In Situ Hybridization

    15.3. Market Value Forecast By End User, 2016–2026

        15.3.1. Hospital Associated Labs

        15.3.2. Independent Diagnostic Laboratories

        15.3.3. Diagnostic Imaging Centers

        15.3.4. Cancer Research Institutes

        15.3.5. Others

    15.4. Market Value Forecast By Indication, 2016–2026

        15.4.1. Breast Cancer

        15.4.2. Lung Cancer

        15.4.3. Colorectal Cancer

        15.4.4. Melanoma

        15.4.5. Blood Cancers

        15.4.6. Prostate Cancer

        15.4.7. Ovarian Cancer

        15.4.8. Stomach Cancer

        15.4.9. Liver Cancer

        15.4.10. Others

    15.5. Market Value Forecast By Country, 2016–2026

        15.5.1. CGG Countries

        15.5.2. South Africa

        15.5.3. Rest of MEA

    15.6. Market Attractiveness Analysis

        15.6.1. By Test 

        15.6.2. By End User 

        15.6.3. By Indication 

        15.6.4. By Country

    15.7. Drivers and Restraints: Impact Analysis 

16. Competition Landscape

    16.1. Competition Dashboard

    16.2. Market Share Analysis By Company (2015)

    16.3. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)

        16.3.1. Abbott Laboratories

        16.3.2. Hoffmann-La Roche Ltd. 

        16.3.3. Thermo Fisher Scientific Inc. 

        16.3.4. Thermo Fisher Scientific Inc. 

        16.3.5. Siemens AG 

        16.3.6. Bio Rad Laboratories Inc. 

        16.3.7. GE Healthcare  

        16.3.8. Illumina, Inc. 

        16.3.9. Koninklijke Philips N.V. 

        16.3.10. Toshiba Medical Systems Corporation 

        16.3.11. Agilent Technologies, Inc. 

17. Assumptions and Acronyms Used

18. Research Methodology

Cancer Diagnostics Market Reports - List of Tables

  1. Global Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026

  2. Global Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026

  3. Global Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Indication, 2015 – 2026

  4. Global Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By End User, 2015 – 2026

  5. Global Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Region, 2015 – 2026

  6. North America Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026

  7. North America Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026

  8. North America Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026

  9. North America Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Indication, 2015 – 2026

  10. North America Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By End User, 2015 – 2026

  11. Latin America Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026

  12. Latin America Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026

  13. Latin America Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026

  14. Latin America Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Indication, 2015 – 2026

  15. Latin America Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By End User, 2015 – 2026

  16. Western Europe Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026

  17. Western Europe Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026

  18. Western Europe Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026

  19. Western Europe Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Indication, 2015 – 2026

  20. Western Europe Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By End User, 2015 – 2026

  21. Eastern Europe Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026

  22. Eastern Europe Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026

  23. Eastern Europe Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026

  24. Eastern Europe Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Indication, 2015 – 2026

  25. Eastern Europe Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By End User, 2015 – 2026

  26. APEJ Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026

  27. APEJ Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026

  28. APEJ Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026

  29. APEJ Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Indication, 2015 – 2026

  30. APEJ Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By End User, 2015 – 2026

  31. Japan Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026

  32. Japan Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026

  33. Japan Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Indication, 2015 – 2026

  34. Japan Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By End User, 2015 – 2026

  35. MEA Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026

  36. MEA Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026

  37. MEA Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026

  38. MEA Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Indication, 2015 – 2026

  39. MEA Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By End User, 2015 – 2026

Cancer Diagnostics Market Reports - List of Figures

  1. Global Cancer Diagnostics Market Value Analysis and Forecast, 2015–2026 (US$ Mn)

  2. Global Cancer Diagnostics Market Share Analysis (%) By Test Type, 2016 & 2026

  3. Global Cancer Diagnostics Market Y-o-Y Growth (%) By Test Type, 2016–2026

  4. Global Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn) By Tumor Biomarker Tests, 2015 – 2026

  5. Global Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn) Imaging Tests, 2015 – 2026

  6. Global Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn) By Liquid Biopsy, 2015 – 2026

  7. Global Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn) Biopsy/Tissue Diagnostics Tests, 2015 – 2026

  8. Global Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn) Immunohistochemistry Tests, 2015 – 2026

  9. Global Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn) In Situ Hybridization, 2015 – 2026

  10. Global Cancer Diagnostics Market Attractiveness Analysis By Test Type, 2016–2026

  11. Global Cancer Diagnostics Market Share Analysis (%) By Indication, 2016 & 2026

  12. Global Cancer Diagnostics Market Y-o-Y Growth (%) By Indication, 2016–2026

  13. Global Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn) By Breast Cancer, 2015 – 2026

  14. Global Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn) Lung Cancer, 2015 – 2026

  15. Global Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn) By Colorectal Cancer, 2015 – 2026

  16. Global Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn) Melanoma, 2015 – 2026

  17. Global Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn) By Blood Cancer, 2015 – 2026

  18. Global Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn) Prostate Cancer, 2015 – 2026

  19. Global Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn) By Ovarian Cancer, 2015 – 2026

  20. Global Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn) Stomach Cancer, 2015 – 2026

  21. Global Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn) By Liver Cancer, 2015 – 2026

  22. Global Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn) By Other Indications, 2015 – 2026

  23. Global Cancer Diagnostics Market Attractiveness Analysis By Indication, 2016–2026

  24. Global Cancer Diagnostics Market Share Analysis (%) By End User, 2016–2026

  25. Global Cancer Diagnostics Market Y-o-Y Growth (%) By End User, 2015–2026

  26. Global Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn) By Hospital Associated Labs, 2015 – 2026

  27. Global Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn) By Independent Diagnostic Laboratories, 2015 – 2026

  28. Global Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn) By Diagnostic Imaging Centers, 2015 – 2026

  29. Global Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn) By Cancer Research Institutes, 2015 – 2026

  30. Global Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn) By Others, 2015 – 2026

  31. Global Cancer Diagnostics Market Attractiveness Analysis By End User, 2016–2026

  32. Global Cancer Diagnostics Market Share Analysis (%) By Region, 2016 & 2026

  33. Global Cancer Diagnostics Market Y-o-Y Growth (%) By Region, 2015–2026

  34. North America Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

  35. Latin America Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

  36. Western Europe Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

  37. Eastern Europe Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

  38. APEJ Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

  39. Japan Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

  40. MEA Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

  41. Global Cancer Diagnostics Market Attractiveness Analysis By Region, 2016–2026

  42. North America Cancer Diagnostics Market Share Analysis (%) By Country, 2016, 2026

  43. North America Cancer Diagnostics Market Y-o-Y Growth (%) By Country, 2015–2026

  44. U.S. Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

  45. Canada Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

  46. North America Cancer Diagnostics Market Attractiveness Analysis By Country, 2016 – 2026

  47. North America Cancer Diagnostics Market Attractiveness Analysis By Test Type, 2016 – 2026

  48. North America Cancer Diagnostics Market Attractiveness Analysis By Indication, 2016 – 2026

  49. North America Cancer Diagnostics Market Attractiveness Analysis By End User, 2016 – 2026

  50. Latin America Cancer Diagnostics Market Share Analysis (%) By Country, 2016 & 2026

  51. Latin America Cancer Diagnostics Market Y-o-Y Growth (%) By Country, 2015–2026

  52. Brazil Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

  53. Mexico Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

  54. Rest of Latin America Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

  55. Latin America Cancer Diagnostics Market Attractiveness Analysis By Country, 2016 – 2026

  56. Latin America Cancer Diagnostics Market Attractiveness Analysis By Test Type, 2016 – 2026

  57. Latin America Cancer Diagnostics Market Attractiveness Analysis By Indication, 2016 – 2026

  58. Latin America Cancer Diagnostics Market Attractiveness Analysis By End User, 2016 – 2026

  59. Western Europe Cancer Diagnostics Market Share Analysis (%) By Country, 2016 & 2026

  60. Western Europe Cancer Diagnostics Market

  61. Germany Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

  62. Italy Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

  63. France Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

  64. U.K. Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

  65. Spain Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

  66. Rest Of Western Europe Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

  67. Western Europe Cancer Diagnostics Market Attractiveness Analysis By Country, 2016 – 2026

  68. Western Europe Cancer Diagnostics Market Attractiveness Analysis By Test Type, 2016 – 2026

  69. Western Europe Cancer Diagnostics Market Attractiveness Analysis By Indication, 2016 – 2026

  70. Western Europe Cancer Diagnostics Market Attractiveness Analysis By End User, 2016 – 2026

  71. Eastern Europe Cancer Diagnostics Market Share Analysis (%) By Country, 2016 & 2026

  72. Eastern Europe Cancer Diagnostics Market Y-o-Y Growth (%) By Country, 2015–2026

  73. Poland Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

  74. Russia Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

  75. Rest of Eastern Europe Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

  76. Eastern Europe Cancer Diagnostics Market Attractiveness Analysis By Country, 2016 – 2026

  77. Eastern Europe Cancer Diagnostics Market Attractiveness Analysis By Test Type, 2016 – 2026

  78. Eastern Europe Cancer Diagnostics Market Attractiveness Analysis By Indication, 2016 – 2026

  79. Eastern Europe Cancer Diagnostics Market Attractiveness Analysis By End User, 2016 – 2026

  80. APEJ Cancer Diagnostics Market Share Analysis (%) By Country, 2016 & 2026

  81. APEJ Cancer Diagnostics Market Y-o-Y Growth (%) By Country, 2015–2026

  82. China Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

  83. India Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

  84. ASEAN Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

  85. Australia and New Zealand Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

  86. Rest of APEJ Europe Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

  87. APEJ Cancer Diagnostics Market Attractiveness Analysis By Country, 2016 – 2026

  88. APEJ Cancer Diagnostics Market Attractiveness Analysis By Test Type, 2016 – 2026

  89. APEJ Cancer Diagnostics Market Attractiveness Analysis By Indication, 2016 – 2026

  90. APEJ Cancer Diagnostics Market Attractiveness Analysis By End User, 2016 – 2026

  91. Japan Cancer Diagnostics Market Attractiveness Analysis By Test Type, 2016 – 2026

  92. Japan Cancer Diagnostics Market Attractiveness Analysis By Indication 2016 – 2026

  93. Japan Cancer Diagnostics Market Attractiveness Analysis By End User 2016 – 2026

  94. MEA Cancer Diagnostics Market Share Analysis (%) By Country, 2016, 2026

  95. MEA Cancer Diagnostics Market Y-o-Y Growth (%) By Country, 2015–2026

  96. GCC Countries Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

  97. South Africa Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

  98. Rest of MEA Europe Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

  99. MEA Cancer Diagnostics Market Attractiveness Analysis By Country, 2016 – 2026

  100. MEA Cancer Diagnostics Market Attractiveness Analysis By Test Type, 2016 – 2026

  101. MEA Cancer Diagnostics Market Attractiveness Analysis By Indication, 2016 – 2026

  102. MEA Cancer Diagnostics Market Attractiveness Analysis By End User, 2016 – 2026